Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596895 · ClinicalTrials.gov registry record · Phase 2
Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer
A Phase 2 study of Biochemical Recurrent Prostate Cancer, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00596895 is a Phase 2 study of Biochemical Recurrent Prostate Cancer that has completed, run by University of Florida. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00596895, a Phase 2 study of Biochemical Recurrent Prostate Cancer, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Outcome Measures: Decrease in rate of serum PSA rise Secondary Outcome Measures: Adherence to treatment regimens Quality of life as assessed by FACT-P at baseline and at 12 months of treatment Modulation of serum testosterone,isoflavone metabolites, and cholesterol Estimated Enrollment: 27 Study Start Date: November 2003 Estimated Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Isoflavone
Study Locations (1)
Florida
- University of Florida Shands - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00596895
The ClinicalTrials.gov registry entry for NCT00596895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Biochemical Recurrent Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Isoflavone is the first listed.
NCT00596895 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00596895 about?
NCT00596895 is a clinical study titled "Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer". Primary Outcome Measures: Decrease in rate of serum PSA rise Secondary Outcome Measures: Adherence to treatment regimens Quality of life as assessed by FACT-P at baseline and at 12 months of treatment Modulation of serum testosterone,isoflavone metabolites, and cholesterol Estimated Enrollment...
What is the current status of trial NCT00596895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-11. Estimated completion is 2007-11.
What conditions does trial NCT00596895 study?
This clinical trial studies the following conditions: Biochemical Recurrent Prostate Cancer.
What interventions are being tested in trial NCT00596895?
The interventions under investigation include: Isoflavone (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00596895?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00596895 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biochemical Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.